RVP

Drug Catalog - Product Detail

TRIAMTERENE W/HCTZ CAP. CP 37.5/25MG 100

NDC Mfr Size Str Form
00781-2074-01 SANDOZ 100 37.5-25MG CAPSULE
Product Image
Generic Name
Substance Name
Product Type
Route
Application Number
Description
DESCRIPTION Triamterene is an antikaliuretic agent and hydrochlorothiazide is a diuretic/antihypertensive agent. At 50°C, triamterene is practically insoluble in water (less than 0.1%). It is soluble in formic acid, sparingly soluble in methoxyethanol, and very slightly soluble in alcohol. Triamterene is 2,4,7-triamino-6-phenylpteridine with a chemical formula of C 12 H 11 N 7 and a molecular weight of 253.27. The structural formula for triamterene is: TRIAMTERENE Hydrochlorothiazide is slightly soluble in water. It is soluble in dilute ammonia, dilute aqueous sodium hydroxide, and dimethylformamide. It is sparingly soluble in methanol. Hydrochlorothiazide is 6-chloro-3,4-dihydro-2 H -1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide with a chemical formula of C 7 H 8 ClN 3 O 4 S 2 and a molecular weight of 297.75. The structural formula for hydrochlorothiazide is: HYDROCHLOROTHIAZIDE Each capsule, for oral administration, contains 37.5 mg triamterene and 25 mg hydrochlorothiazide or 50 mg triamterene and 25 mg hydrochlorothiazide. The 37.5 mg triamterene and 25 mg hydrochlorothiazide capsule inactive ingredients include: citric acid, corn starch, glycine, anhydrous lactose, magnesium stearate, Polysorbate 80, povidone, and sodium starch glycolate. The capsule shells and imprinting inks contain: D & C Yellow #10 Aluminum Lake, FD & C Blue #1 Aluminum Lake, FD & C Blue #2 Aluminum Lake, FD & C Red #40 Aluminum Lake, gelatin, pharmaceutical glaze, propylene glycol, synthetic black iron oxide, and titanium dioxide. The 37.5 mg triamterene and 25 mg hydrochlorothiazide capsule meets USP Dissolution Test 3 . The 50 mg triamterene and 25 mg hydrochlorothiazide capsule inactive ingredients include: lactose monohydrate, magnesium stearate, povidone, corn starch. The capsule shells and imprinting inks contain: D&C Red # 40, gelatin, titanium dioxide, pharmaceutical glaze, propylene glycol and simethicone. The 50 mg triamterene and 25 mg hydrochlorothiazide capsule meets USP Dissolution Test 2 . Triamterene Chemical Fromula Hydrochlorothiazide Chemical Structure
How Supplied
HOW SUPPLIED Capsules containing 37.5 mg triamterene and 25 mg hydrochlorothiazide are available for oral administration as white capsules with single black ink bands imprinted GG 606 in black ink and supplied as: NDC 0781-2074-01 bottles of 100 NDC 0781-2074-10 bottles of 1000 Capsules containing 50 mg triamterene and 25 mg hydrochlorothiazide are available for oral administration as opaque red cap/opaque red body, body and cap imprinted GG 580 in white ink, filled with yellow powder and supplied as: NDC 0781-2715-01 bottles of 100 NDC 0781-2715-10 bottles of 1000 NDC 0781-2715-13 unit dose packages of 100 Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Protect from moisture. Protect from light. Dispense in a tight, light-resistant container. 08-2011M 7379 Sandoz Inc. Princeton, NJ 08540
Indications & Usage
INDICATIONS AND USAGE This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide capsules are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide capsules are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the action of these agents, dosage adjustments may be necessary. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate.
Dosage and Administration
DOSAGE AND ADMINISTRATION The usual dose of triamterene and hydrochlorothiazide capsules is one or two capsules given once daily, with appropriate monitoring of serum potassium and of the clinical effect. (See WARNINGS: Hyperkalemia .)